Navigation Links
Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinson's Disease
Date:9/10/2013

BOSTON, Sept. 10, 2013 /PRNewswire/ -- Rhythm announced today that The Michael J. Fox Foundation for Parkinson's Research (MJFF) has awarded a $1.35 million research grant to Rhythm to help fund a Phase 2 clinical trial of RM-131, the company's novel ghrelin agonist, for the treatment of refractory constipation in patients with Parkinson's disease (PD). This study expands the ongoing Phase 2 clinical program for RM-131 for the treatment of both upper and lower gastrointestinal (GI) functional disorders.

"As we work toward a cure for Parkinson's, alleviating the symptoms of disease is our best approach to improve quality of life for the millions living with PD. Development of a treatment for painful and debilitating constipation will have significant meaning to this population," said Maurizio Facheris, MD, MJFF associate director of research programs.

Constipation is common among people with Parkinson's, with studies reporting more than 50% of PD patients suffering from moderate to severe constipation. Many of these patients are refractory to existing therapy. In addition, GI dysfunction in PD can affect the upper GI tract, resulting in gastroparesis. Overall, the symptoms of upper and lower GI functional disorders can be debilitating and disruptive to the lives of PD patients and, in addition, may undermine the GI absorption of L-DOPA in the intestine, interfering with this drug's effectiveness. Approximately one million people in the U.S. are living with Parkinson's disease.

"Refractory constipation is a significant issue in Parkinson's disease, and this first study of RM-131 in Parkinson's patients is focused on this disorder," said Keith Gottesdiener, MD, CEO of Rhythm. "As we continue our work to advance RM-131 in the clinic, we are excited to join with The Michael J. Fox Foundation to address this important unmet need in Parkinson's disease."

About the Study

The Phase
'/>"/>

SOURCE Rhythm
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
2. Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor
3. Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
4. Rhythmic firing of nerve cells involved in bodys movements
5. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
6. Rap music powers rhythmic action of medical sensor
7. Rhythm Names Lex Van der Ploeg Chief Scientific Officer
8. VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
9. Fumio Hirakawa has been awarded with the notable Golden A' Design Award
10. Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction
11. VG Energy Chief Scientist Awarded $200,000 AgriLife Grant to Study Lipid Secretion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 ... portfolio company of Trendlines Agtech , announced ... Israel,s leading agricultural thermoplastics ... Valentis,s technology combines nanocrystalline cellulose (NCC), ... waste, with additional nanoparticles to produce highly improved ...
(Date:7/23/2014)... - BioAmber Inc. (NYSE: BIOA ), ... that the underwriters of its common stock offering ... additional 420,000 shares of common stock at the ... underwriting discounts and commissions, in connection with its ... of common stock, bringing the expected net proceeds ...
(Date:7/23/2014)... July 23, 2014 Shire ... the global specialty biopharmaceutical company, and ArmaGen, a ... worldwide licensing and collaboration agreement for AGT-182, an ... treatment of both the central nervous system (CNS) ... (MPS II). This collaboration strengthens Shire,s rare disease ...
(Date:7/23/2014)... MENLO PARK, Calif. , July 23, 2014 /PRNewswire/ ... based investment firm, today announced the closing of Sofinnova ... $500 million and in excess of the initial fund ... on helping entrepreneurs build successful biotechnology companies. Consistent with ... companies with promising later stage clinical programs, along with ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5Sofinnova Raises $500 Million Biotech Venture Fund 2
... 13 leading industry speakers will present at CBI,s 2nd ... on November 14-15, 2011 in Philadelphia. Nearly 100 TMF professionals ... shift taking place in the clinical trials -- moving from ... the heart of a clinical trial, the TMF is re-examined ...
... SEATTLE, Oct. 26, 2011 Immune Design Corp. ... vaccines and immunotherapies for infectious disease, cancer and ... an early-stage research collaboration with Sanofi-Aventis to investigate ... technology, a toll–like receptor 4 (TLR-4) agonist, in ...
... from this smorgasbord of recent salmonella outbreaks in the ... in 2011 alone, and the list goes on, according ... But perhaps not for long, thanks to a promising ... salmonella bacteria before contaminated food or animals reach the ...
Cached Biology Technology:
(Date:7/22/2014)... that feature natural habitats and trees and not just ... according to a University of Colorado Boulder study. , ... also provide stress-reducing benefits for youth, according to a ... The study is one of the first of ... access to green settings and stress. , "Many schools ...
(Date:7/22/2014)... prevent their daughters from breeding, and kill their grandchildren ... desert creatures which live in groups with a dominant ... alpha female can flourish when it maintains the sole right ... life, also found in many animals such as ants and ... Dominant meerkats control breeding within their group through violence, by ...
(Date:7/22/2014)... the genus of planthopper known as Conosimus, which now ... discovered in the southern part of the Iberian Peninsula ... it appears in the open-access Journal of Insect ... species, Conosimus baenai , has been named after ... the taxonomy of Iberian Hemiptera. , Conosimus baenai ...
Breaking Biology News(10 mins):Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3
... , This release is available in French ... researchers have discovered a novel molecular mechanism that prevents cancer. ... Molecular Cell , scientists from the Universit de Montral and ... SOCS1 molecule prevents the cancer-causing activity of cytokines, hormones that ...
... amount of weight by eating less and exercising more improved ... of Medicine in St. Louis. The results of this ... the Journal of the American College of Cardiology , ... measures of heart and vascular health. The improvements seen in ...
... from 190 nations are gathered at the two-week ... about 150 distinguished guests attended an ESA-hosted side ... Essential Climate Variables,. During the event, speakers ... observation satellites play in providing systematic global climate ...
Cached Biology News:Scientists identify natural anti-cancer defenses 2Moderate weight loss in obese people improves heart function 2Moderate weight loss in obese people improves heart function 3Space agencies join forces to systematically observe climate variables 2Space agencies join forces to systematically observe climate variables 3
... Recognizes Nabeta2. The epitope ... present in any other known ... expected to work on human ... highly conserved (17/19 residues). Reactivity ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
... for DNA isolation. Designed to ... 96 well plate adapters from Mo ... entire plate length (max capacity is ... used for soil, microorganisms, animal tissue, ...
Biology Products: